The targets of additional CARs that demonstrated promising in vivo results in CRC models—and that are now in clinical trials—include EpCAM [166,167], GUCY2C [168,169], NKG2D [170], and HER2 [171] (Table 2). This evidence concerns the gene EPCAM and colorectal carcinoma.